Silicon Laboratories Inc. — Form 10-Q Summary
Period and filing: The supplied filing covers the quarter ended September 27, 2014, and the nine months then ended; it compares results with the corresponding 2013 periods. This conflicts with the request metadata identifying “2013 Q3”; the filing itself is for 2014 Q3.
Business context
Silicon Laboratories designs analog-intensive mixed-signal integrated circuits for communications, consumer, industrial and automotive markets. It operates a fabless model, relying on third parties for wafer fabrication, assembly and testing. For the first nine months of 2014, 85% of revenue was from outside the United States; Samsung represented more than 10% of revenue, and two distributors each exceeded 10%.
Financial performance
Amounts below are in millions of dollars except per-share data and percentages.
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Revenue | $158.1 | $146.9 | $458.8 | $433.9 |
| Gross margin | $96.1; 60.8% | $88.2; 60.0% | $281.9; 61.4% | $264.3; 60.9% |
| Operating income | $9.6 | $10.5 | $40.4 | $50.2 |
| Net income | $5.6 | $6.5 | $28.0 | $39.2 |
| Diluted EPS | $0.13 | $0.15 | $0.64 | $0.90 |
| Operating cash flow | Not separately reported | Not separately reported | $107.6 | $95.2 |
- Quarterly revenue grew 7.6%; nine-month revenue grew 5.7%. Q3 growth reflected higher Broad-based, Broadcast and Access sales. Nine-month gains were led by Broad-based products; Access revenue declined.
- Q3 product unit volume rose 10.9%, while average selling prices fell 4.2%. For the nine-month period, volume increased 3.2% and average selling prices increased 1.0%.
- Profitability weakened despite higher revenue and gross margin. Operating expenses rose 11.4% in Q3, led by SG&A, which increased 18.9%; nine-month SG&A rose 16.3%. Management attributed higher costs to acquisition-related contingent consideration, personnel and litigation expenses.
- Patent sales contributed $2.1 million of Q3 revenue and $7.1 million for the nine months, with no associated cost of revenue.
Liquidity, cash flow and debt
- At September 27, 2014, cash and cash equivalents were $111.7 million and short-term investments were $217.0 million, totaling $328.7 million. Current assets were $504.9 million and current liabilities were $152.7 million.
- Term-loan debt was $91.25 million: $11.25 million current and $80.0 million long-term. The $130 million revolving facility was undrawn. The company reported compliance with its credit covenants.
- Nine-month operating cash flow was $107.6 million. Investing activities used $46.2 million and financing activities used $45.5 million. Financing outflows included $50.9 million of share repurchases; the company repurchased 1.3 million shares for $53.9 million during the period.
- Management said existing cash, investments and available credit were sufficient for expected requirements through at least the next 12 months. Fiscal 2014 capital expenditures were projected at approximately $10–$14 million.
Outlook, commentary and material risks
- Q4 2014 guidance: revenue of $155–$161 million and diluted EPS of $0.12–$0.18. Management expected R&D expense to rise in Q4 and SG&A expense to decline, primarily as acquisition-related costs eased.
- Q3 included a $6.0 million earnings loss from remeasurement of acquisition-related contingent consideration, after the company raised its estimate of expected Energy Micro earn-out achievement. The filing also identifies higher legal costs, primarily related to litigation.
- All $12.4 million par value of auction-rate securities remained subject to failed auctions, with contractual maturities from 2033 to 2046. Their recorded fair value was $11.5 million; management reported no other-than-temporary impairment and did not expect to need the funds before maturity.
- A wafer supplier for high-voltage products, Telefunken Semiconductors, entered insolvency proceedings. Silicon Laboratories arranged limited wafer purchases through 2014 and accelerated a manufacturing transition; supply interruption or customer requalification delays could hurt sales.
- Cresta Technology litigation includes claims against the company and certain customers concerning television tuner patents; the company said the outcome and financial impact could not be predicted. The company also pursued patent claims against Cresta; one related ITC investigation ended after a consent order restricting certain Cresta products.
- Other disclosed risks include customer and distributor concentration, dependence on third-party manufacturing, semiconductor cyclicality, pricing pressure, lengthy design-win and qualification cycles, and foreign-market exposure. Management described forward-looking statements as subject to risks and uncertainty.
Key facts for investors to verify
- Confirm the reporting-period mismatch: the filing is for Q3 2014, not Q3 2013.
- Assess whether revenue growth can translate into improved earnings given higher operating expenses, tax rates and acquisition-related charges.
- Track Q4 revenue and EPS against management’s guidance and monitor product mix, unit volumes and average selling prices.
- Review the status of the Telefunken supply transition, Cresta litigation and contingent consideration estimates.
- Evaluate the accessibility and valuation assumptions for auction-rate securities, and the effect of continued repurchases on cash and share count.